Proteomic tool vendors may not see much benefit from the $10.4 billion stimulus package passed by the US government in February, according to a report from an investment firm.
Last week, Thomas Weisel Partners issued a report on a survey of 54 life-science researchers that sought to gauge the current funding environment, expectations for future funding, and likely beneficiaries.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
